source
- ARM playbook proposes data reuse to slash gene-editing R&D costs and broaden rare-disease therapiesThe Alliance for Regenerative Medicine released a new playbook that outlines how developers of gene‑editing therapies can reuse existing data to lower research and development expenses. The guidanc…
- Viatris to acquire Pacira BioSciences for $1.65 billion, expanding its non‑opioid pain portfolioViatris, a maker of generic and branded medicines, announced a cash purchase of commercial‑stage Pacira BioSciences for $1.65 billion. The deal adds Pacira’s non‑opioid pain treatments to Viatris’…